We are live on ! Find out more
EHI

Eagle Health Investments Portfolio holdings

AUM $603M
1-Year Est. Return 111.06%
This Fund
S&P 500
This Quarter Est. Return
+15.4%
1 Year Est. Return
+111.06%
3 Year Est. Return
+240.87%
5 Year Est. Return
+290.92%
10 Year Est. Return
–
AUM
$528M
AUM Growth
-$42.2M
Cap. Flow
-$91.6M
Cap. Flow %
-17.34%
Top 10 Hldgs %
71.71%
Holding
27
New
1
Increased
4
Reduced
8
Closed
2

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$17.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$15.7M
3
DXCM icon
DexCom
DXCM
+$14.4M
4
ILMN icon
Illumina
ILMN
+$8.46M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$1.89M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$38.3M
2
IQV icon
IQVIA
IQV
+$25.8M
3
UNH icon
UnitedHealth
UNH
+$20.5M
4
GH icon
Guardant Health
GH
+$18.1M
5
TMDX icon
Transmedics
TMDX
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$46.4B
$54.8M 10.37%
431,314
-42,800
-9% -$4.91M
ILMN icon
2
Illumina
ILMN
$29B
$50.5M 9.57%
387,354
+68,600
+22% +$8.46M
ARGX icon
3
argenx
ARGX
$54.2B
$40.7M 7.7%
74,990
-13,900
-16% -$7.02M
ICLR icon
4
Icon
ICLR
$12.9B
$37.6M 7.12%
130,790
-18,800
-13% -$5.93M
INSM icon
5
Insmed
INSM
$29.5B
$37.5M 7.1%
513,700
– –
EXAS
6
DELISTED
Exact Sciences
EXAS
$37.1M 7.02%
544,200
– –
RARE icon
7
Ultragenyx Pharmaceutical
RARE
$2.65B
$31.2M 5.91%
561,700
+37,200
+7% +$1.89M
DXCM icon
8
DexCom
DXCM
$33.2B
$30.3M 5.73%
451,492
+175,774
+64% +$14.4M
UNH icon
9
UnitedHealth
UNH
$371B
$29.6M 5.61%
50,700
-36,200
-42% -$20.5M
BMRN icon
10
BioMarin Pharmaceuticals
BMRN
$13.3B
$29.5M 5.58%
419,212
+187,412
+81% +$15.7M
INSP icon
11
Inspire Medical Systems
INSP
$1.73B
$28.8M 5.46%
136,603
– –
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$29B
$21M 3.97%
76,256
– –
UTHR icon
13
United Therapeutics
UTHR
$22.7B
$19.4M 3.67%
54,099
-113,400
-68% -$38.3M
PRCT icon
14
Procept Biorobotics
PRCT
$1.26B
$18.7M 3.54%
233,089
-24,000
-9% -$1.71M
NBIX icon
15
Neurocrine Biosciences
NBIX
$16.7B
$14.8M 2.81%
+128,600
New +$17.6M
AGIO icon
16
Agios Pharmaceuticals
AGIO
$1.94B
$14.7M 2.78%
330,830
– –
CRSP icon
17
PUT
CRISPR Therapeutics
CRSP
$5.17B
$9.26M 1.75%
197,000
– –
FDMT icon
18
4D Molecular Therapeutics
FDMT
$572M
$5M 0.95%
462,911
– –
LNTH icon
19
Lantheus
LNTH
$6.59B
$4.74M 0.9%
43,200
– –
ISRG icon
20
Intuitive Surgical
ISRG
$138B
$3.63M 0.69%
7,390
-20,900
-74% -$9.73M
VKTX icon
21
Viking Therapeutics
VKTX
$3.98B
$2.85M 0.54%
45,000
– –
TMDX icon
22
Transmedics
TMDX
$3.05B
$2.84M 0.54%
18,061
-114,800
-86% -$17.7M
HOWL icon
23
Werewolf Therapeutics
HOWL
$19M
$1.48M 0.28%
700,000
– –
IMCR icon
24
Immunocore
IMCR
$1.73B
$1.44M 0.27%
46,300
– –
GRAL
25
GRAIL Inc
GRAL
$3.29B
$731K 0.14%
53,124
– –
1
2

Similar funds

PIFP
Partners in Financial Planning Salem, Virginia $603M AUM 12.72% 1-Year Est. Return
IECM
Intrinsic Edge Capital Management Chicago, Illinois $603M AUM 66.97% 1-Year Est. Return
ERWM
Elk River Wealth Management Denver, Colorado $602M AUM 22.77% 1-Year Est. Return
CIG
Capricorn Investment Group Palo Alto, California $602M AUM 165.22% 1-Year Est. Return
JHCP
Jackson Hole Capital Partners Tulsa, Oklahoma $605M AUM 22.77% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
NPCM
North Peak Capital Management New York $601M AUM 0.2% 1-Year Est. Return
OCAM
Onex Canada Asset Management Toronto, Ontario, Canada $601M AUM 15.16% 1-Year Est. Return

Eagle Health Investments's Q3 2024 Portfolio in Review

As of Q3 2024, Eagle Health Investments held 27 positions worth $528M, down 7.4% from $570M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Eagle Health Investments withdrew a net $91.6M in Q3 2024, closing 2 positions and reducing 8 holdings. Its most notable exit was IQVIA, an estimated $25.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

Against the trend, Eagle Health Investments opened a new position in Neurocrine Biosciences worth $14.8M.

  • Eagle Health Investments's largest Q3 2024 buy was Neurocrine Biosciences: 128,600 shares worth $14.8M.
  • Eagle Health Investments added most to BioMarin Pharmaceuticals in Q3 2024, an estimated $15.7M increase.
  • Eagle Health Investments's biggest Q3 2024 reduction was United Therapeutics, cutting an estimated $38.3M.
  • Eagle Health Investments fully exited IQVIA in Q3 2024, selling an estimated $25.8M.
  • Eagle Health Investments's ten largest holdings make up 72% of its $528M portfolio in Q3 2024.
  • Eagle Health Investments opened 1 new position and closed 2 in Q3 2024.
  • Eagle Health Investments's portfolio value fell 7.4% quarter-over-quarter to $528M.

Based on Eagle Health Investments's 13F filing for Q3 2024, filed 12 Nov 2024.